April 10, 2020

A message from our CEO to the World Federation of Hemophilia:

As the Covid-19 virus situation evolves, we know that the needs of our patients remain the same, and we are committed to our promise of making and delivering life-saving medicines to those who depend on them. We understand that managing a chronic illness during this time can be stressful and you likely have concerns about the safety and availability of your medicines.

I personally want to assure you that our CSL Behring business, including our manufacturing and plasma collection centers, is operating. Despite the current environment, we continue to deliver an uninterrupted supply of our treatments and, as always, are committed to the highest standards of safety and quality for our products, donors and employees.

This global pandemic is a humanitarian crisis that impacts us all. As a leading biotherapeutics company, we understand the responsibilities we have to deliver innovative solutions for high unmet medical needs. That is why I am proud to share with you that CSL Behring was instrumental in forming an unprecedented industry alliance to help develop a therapy for treating people with COVID-19. Together with other plasma-product companies including Biotest, BPL, LFB, Octapharma and Takeda, we will begin work immediately on the development of an anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. We believe that by bringing together the brightest minds, and leveraging collective resources and expertise, we can achieve more than by working independently. Please refer to our website for more information at cslbehring.com.

On behalf of everyone at CSL Behring, my thoughts are with you and your family, friends, and communities as you manage through these uncertain times, but I am very optimistic about the work we are doing to develop a reliable, scalable and sustainable treatment solution for this devastating pandemic.

Thank you for your trust in CSL Behring. Be safe and be well.

Paul Perreault
CEO and Managing Director
CSL Limited
CSL Behring’s Global Role in Battling COVID-19

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

- CSL Behring is part the CoVig-19 Plasma Alliance, an unprecedented industry partnership to develop CoVig-19, a potential plasma-derived therapy for treating COVID-19. The CoVig-19 Plasma Alliance will work toward developing the unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19, and to support national governments in their efforts to fight the current pandemic. The collaboration will leverage leading-edge expertise and work that the companies already have underway.

- Collaborating with the University of Queensland in Australia, whom CSL has a long-standing relationship, to support the development of a COVID-19 vaccine candidate. The company is providing its vaccine development expertise, proprietary technologies and laboratory facilities to optimize the chances of success.

- Donation of Seqirus' well-established adjuvant technology – MF59® – to multiple entities searching for a COVID-19 vaccine. MF59® is used in the company's adjuvanted seasonal flu vaccine for the over-65 age group -- one of the most vulnerable populations to COVID-19. Adjuvants can help improve immune response and reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly... In parallel, Seqirus remains focused on the production of seasonal influenza vaccines for upcoming season, the importance of which is very much underscored by the COVID-19 pandemic.

- Partnering with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, to advance and deliver a novel immunotherapy targeting COVID-19. The potential therapy would be produced without the need for blood plasma donations from recovered COVID-19 patients. Clinical trials could begin this summer in North America.

- Engaging with investigators regarding the company's monoclonal antibodies, including CSL312 and CSL324, to identify treatment candidates from the portfolio that have the potential to treat Diffuse Alveolar Damage – one of the devastating respiratory consequences of COVID-19. These are considered much more experimental approaches, but still potentially very important therapies for people who have suffered the potentially devastating impact of COVID-19.

- Additionally, from the time the coronavirus was first identified in Wuhan, China – where CSL Behring has a manufacturing facility – the company has been assisting in the fight against COVID-19 in a number of ways including offering expertise, technologies, equipment and materials on a humanitarian basis.

For the latest information from CSL Behring around its work in the fight against COVID-19, please visit: www.cslbehring.com

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in
more than 70 countries. For inspiring stories about the promise of biotechnology, visit Vita
CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

Media Contact: Natalie de Vane, Natalie.de.Vane@cslbehring.com, 610-999-8756